**Pediococcus pentosaceus** CECT 8330 protects DSS-induced colitis and regulates the intestinal microbiota and immune responses in mice

Fang Dong¹, Fangfei Xiao¹, Xiaolu Li¹, Youran Li¹, Xufei Wang¹, Guangjun Yu², Ting Zhang¹,²* and Yizhong Wang¹,²*

**Abstract**

**Background:** Compelling evidences demonstrated that gut microbiota dysbiosis plays a critical role in the pathogenesis of inflammatory bowel diseases (IBD). Therapies for targeting the microbiota may provide alternative options for the treatment of IBD, such as probiotics. Here, we aimed to investigate the protective effect of a probiotic strain, *Pediococcus pentosaceus* (P. pentosaceus) CECT 8330, on dextran sulfate sodium (DSS)-induced colitis in mice.

**Methods:** C57BL/6 mice were administered phosphate-buffered saline (PBS) or *P. pentosaceus* CECT 8330 (5 × 10⁸ CFU/day) once daily by gavage for 5 days prior to or 2 days after colitis induction by DSS. Weight, fecal conditions, colon length and histopathological changes were examined. ELISA and flow cytometry were applied to determine the cytokines and regulatory T cells (Treg) ratio. Western blot was used to examine the tight junction proteins (TJP) in colonic tissues. Fecal short-chain fatty acids (SCFAs) levels and microbiota composition were analyzed by targeted metabolomics and 16S rRNA gene sequencing, respectively. The Kyoto Encyclopedia of Genes and Genomes (KEGG) and Cluster of orthologous groups of proteins (COG) pathway analysis were used to predict the microbial functional profiles.

**Results:** *P. pentosaceus* CECT 8330 treatment protected DSS-induced colitis in mice as evidenced by reducing the weight loss, disease activity index (DAI) score, histological damage, and colon length shortening. *P. pentosaceus* CECT 8330 decreased the serum levels of proinflammatory cytokines (TNF-α, IL-1β, and IL-6), and increased level of IL-10 in DSS treated mice. *P. pentosaceus* CECT 8330 upregulated the expression of ZO-1, Occludin and the ratio of Treg cells in colon tissue. *P. pentosaceus* CECT 8330 increased the fecal SCFAs level and relative abundances of several protective bacteria genera, including norank_f_Muribaculaceae, Lactobacillus, Bifidobacterium, and Dubosiella. Furthermore, the increased abundances of bacteria genera were positively correlated with IL-10 and SCFAs levels, and negatively associated with IL-6, IL-1β, and TNF-α, respectively. The KEGG and COG pathway analysis revealed that *P. pentosaceus* CECT 8330 could partially recover the metabolic pathways altered by DSS.

**Conclusions:** *P. pentosaceus* CECT 8330 administration protects the DSS-induced colitis and modulates the gut microbial composition and function, immunological profiles, and the gut barrier function. Therefore, *P. pentosaceus* CECT 8330 may serve as a promising probiotic to ameliorate intestinal inflammation.
Keywords: *Pediococcus pentosaceus*, Probiotic, Colitis, Gut microbiota, IBD

Background
Inflammatory bowel diseases (IBD) is a group of inflammatory disorders of the digestive tract that mainly characterized by chronic and relapsing inflammation of the gut mucosa [1]. IBD occurs in both children and adults, which most of the patients are diagnosed at young age [2]. Although IBD is usually considered as a common intestinal inflammatory disease of western countries, it has become a global disease for its rapidly increased prevalence and incidence in newly industrialized countries, including China [3, 4]. The initial clinical symptoms of IBD include diarrhea, abdominal pain, hematochezia, fistulae, and perianal lesions, which may also affect other organs with extraintestinal manifestations [5]. Patients with IBD usually suffered lifelong episodes of remission and relapse that significantly impair their quality of life. Current evidences indicate that multiple factors, including genetic, environmental, immunological and microbial factors, are involved in the pathogenesis of IBD, however, the precise etiology of IBD remains to be fully elucidated [6]. It is assumed that IBD is occurring in genetically susceptible individuals with a dysregulated immune response towards gut microbiota, and under the influence of environmental factors [7].

The human gut microbiota is made up of trillions of microbial cells, including bacteria, viruses, and fungi, which is vital to human health. Gut microbial cells play critical roles in maintaining both local and systemic homeostasis through interacting with the human immune, endocrine and nervous systems [8]. For their high abundance (approximately 99.9% of the cell population), bacteria have been extensively studied as the first targets of gut microbiome in the past decade. Previous studies have demonstrated that IBD is strongly associated with a gut bacterial dysbiosis of reduced biodiversity and imbalance composition [9–14]. Compared with healthy controls, an increase in number of species belonging to phyla Actinobacteria and Proteobacteria, and a decrease in phyla Firmicutes and Bacteroidetes were observed in patients with IBD [15–17]. The abundances of bacteria with anti-inflammatory properties were decreased, while the relative abundances of pro-inflammatory bacteria were increased in patients with IBD [18]. Our previous studies revealed low relative abundances of short-chain fatty acids (SCFAs)-producing bacteria including *Faecalibacterium*, *Clostridium* clusters IV and XIVb, *Roseburia*, and *Ruminococcus* in pediatric Crohn’s disease (CD) patients [19].

Currently, there are only symptomatic treatments for IBD available, such as anti-inflammatory drugs (e.g., 5-Aminosalicylates), immunomodulatory agents (e.g., corticosteroids), and biologic treatments (e.g., tumor necrosis factor (TNF) inhibitors), which aim to reach clinical remission and mucosal healing [20]. However, the current therapies are limited by the variable efficacy, serious side effects and long-term safety. Since compelling evidences demonstrated that gut microbiota dysbiosis is involved in the pathogenesis of IBD, microbial-based and microbial-targeted therapies for restoring gut microbiome balance provide alternative options for the treatment of IBD [21]. Recently, a number of clinical trials have been performed to investigate the efficacy of microbiota-based therapies, including probiotics, prebiotics, symbiotics, and fecal microbiota transplantation (FMT) on IBD therapy [21, 22]. For example, probiotic strains, *E. coli* Nissle 1917, probiotic complex VSL#3 were effective to induce clinical remission in patients with mild or moderate ulcerative colitis (UC), and *Lactobacillus rhamnosus* GG (LGG) alone or combine with mesalazine prolonged clinical remission in UC patients [23, 24]. Thus, well-defined probiotics may have the potential to become an alternative therapy for IBD.

In the current study, we aimed to investigate the protective effect of a probiotic strain, *Pediococcus pentosaceus* (*P. pentosaceus*) CECT 8330 on intestinal inflammation in a DSS-induced colitis mice model. We further examined the effects of *P. pentosaceus* CECT 8330 on regulation of the cytokine levels, gut barrier function, SCFAs levels, and the gut microbiota composition and function changes.

Materials and methods

**P. pentosaceus** CECT 8330 preparation

*P. pentosaceus* CECT 8330 strain isolated from fresh stool of healthy children [25] was recovered from Dipro AB-8330 Drops (AB-Biotics, S/A, Barcelona, Spain) in Man Rogosa Sharpe (MRS, Sigma-Aldrich, USA) plate for 24 h in microaerophilic conditions (5% CO₂) at 37 °C, as previously described [26]. Single colony was picked from the plate and further amplified anaerobically overnight at 37 °C in MRS broth. Bacteria were collected by centrifugation at 1500 × g and 4 °C for 10 min, and resuspended in sterile phosphate-buffered saline (PBS) to a density of 2.5 × 10⁹ CFU/ml after washing with PBS for 3 times.
Animals, probiotic treatment, and colitis induction
C57BL/6 mice (6 weeks old, 18–20 g) purchased from Ziyuan Lab (Zhejiang, China) were housed under standard specific pathogen-free (SPF) laboratory conditions (temperature, 20–24 °C; relative humidity, 50–60%; light cycle, 12/12 h light/dark). All animal experimental procedures in this study were approved by the Animal Ethics Committee of Shanghai Children’s Hospital (SHCH-IACUC-2020-XMSB-10). After one week of acclimation, mice were randomly divided into three groups: Control group, dextran sulfate sodium (DSS) group, and DSS+CECT 8330 group. All mice in the DSS+CECT 8330 group were treated with 200 μL P. pentosaceus CECT 8330 resuspension (5 × 10⁸ CFU) by oral gavage from day −5 to −1 prior to DSS administration. Mice in the control group and DSS group were given 200 μL sterile PBS by oral gavage daily instead of the probiotic (Fig. 1A). From day 0, mice in the DSS group and DSS+CECT 8330 group were given 3% (w/v) DSS (molecular weight: 36–50 kDa, MP Biomedicals, Santa Ana, CA, USA) ad libitum in drinking water for 7 days to induce colitis. Mice in the Control group were given sterile water during the study period. In the experiment including a posttreatment group, mice in the DSS+CECT 8330 (post) group were oral gavaged daily with 200 μL P. pentosaceus CECT 8330 resuspension (5 × 10⁸ CFU) from day 3 to 7 of DSS administration, and same volume of sterile PBS instead of the probiotic was given to the mice in other three group (Additional file 1: Fig. S1A).

Disease activity index and colon mucosal damage index assessments
All mice were monitored daily for body weight and fecal conditions following the initiation of DSS treatment. A disease activity index (DAI) was recorded based on body weight loss (no loss: 0 point; 1–5% loss: 1 point; 5–10% loss: 2 points; 10–15% loss: 3 points; over 15% loss: 4 points), fecal consistency (normal: 0 point; loose stools: 2 points; watery diarrhea: 4 points), and hematochezia (no bleeding: 0 point; slight bleeding: 2 points; gross bleeding: 4 points). The DAI score (0–12) was the total score of above three parameters [27]. The colonic mucosa damage index (CMDI) was assessed at the time of killing on
day 7 by ulceration and inflammation (normal: 0 point; focal hyperemia, no ulcers: 1 point; ulceration without hyperemia or bowel wall thickening: 2 points; ulceration with inflammation at one site: 3 points; two sites of ulceration and inflammation: 4 points; major sites of damage extending ≥ 1 cm along the colon: 5 points; damage extending ≥ 2 cm along the length of the colon, with the score increasing by 1 point for each additional cm of damage: 6–10 points), and presence of adhesions (normal: 0 point; minor adhesions: 1 point; major adhesions: 2 points) [28].

**Histological analysis**

A 5 mm long distal colon sample of each mouse was collected and fixed in 4% paraformaldehyde fixative solution for 24 h, then sample was embedded in paraffin wax. Sample was sliced into 5 μm sections for hematoxylin and eosin (H&E) staining. Randomly selected slices from each group were observed with a pathologic slice scanner at 100 × magnification, and then recorded photomicrographs. A histological index (HI) calculating based on inflammatory cell infiltration (1–3 points) and the intestinal architecture (1–3 points) was used to assess the degree of the histopathological changes, as previously described [29].

**Western blot analysis**

Approximately 50 mg of colon tissue was frozen in liquid nitrogen and pulverized. Total protein was extracted by using 1 × sodium dodecyl sulfate (SDS) lysis buffer with 1% phenylmethylsulfonyl fluoride (PMSF) for 30 min at 4 °C, and the supernatant was collected after centrifugation (12,000 rpm, 5 min). The protein concentration was quantified using the BCA kit. Equal amount of protein (50 μg) was separated by 8% and 10% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) for 2 h and transferred to polyvinylidene difluoride (PVDF) membrane. The membrane was blocked with 5% nonfat milk for 2 h at room temperature and incubated with antibodies specific for GAPDH (Cell Signaling Technology; #5714; 1:1000), β-Actin (Cell Signaling Technology; #8457; 1:1000), ZO-1 (Cell Signaling Technology; #8193; 1:1000), occludin (Bioworld; BS72035; 1:1000), and β-Actin (Cell Signaling Technology; #8457; 1:1000), and detected by Bio-Rad Chemi Doc XRS plus an image analyzer (Bio-Rad, Hercules, CA, USA).

**Serum cytokine analysis**

At the time of sacrifice on day 7, mice were anesthetized with chloral hydrate (2.5%, 0.1 mL/10 g) and removed the eyeballs to collect the blood samples. The serum was obtained by centrifugation at 3000 rpm for 10 min. Cytokines, interleukin-6 (IL-6), IL-10, IL-1β, and TNF-α in the serum were determined using ELISA kits (4A Biotech Co. Ltd., Beijing, China) following the manufacturer’s instructions, respectively.

**Flow cytometry analysis**

The colon tissue selected from 0.5 cm below the cecum to 0.5 cm above the anus was cut longitudinally and then transversely into 0.5 cm pieces after removing adipose tissue, mesenteric connective tissue, and Peyer’s patches. After washing with PBS, colon pieces were digested with collagenase solution containing 1 mg/mL collagenase VIII and 1 U/mL DNase I (Gibco, Life Technologies) for 55 min in a 37 °C shaker. The supernatant was filtered with 40 μm cell strainer, and centrifuged at 2000 rpm for 5 min. The cell suspension was centrifuged after washing with plain RPMI 1640. Lamina propria lymphocytes (LPLs) were separated by density gradient centrifugation (cells were resuspended with 40% Percoll solution, and overlaid with an 80% Percoll solution, at 2500 rpm, 25 min). The interface containing the LPLs were aspirated and washed in medium, and subjected to stain with anti-CD4 (clone GK1.5; eBioscience), anti-CD25 (clone PC61; eBioscience) at 4 °C in the dark for 30 min. Cells were fixed and permeabilized with 200 μL fixation-permeabilization buffer overnight at 4 °C in the dark. Subsequently, cells were incubated intracellularly with Foxp3-PE (clone eBioscience) at 4 °C in the dark for 1 h, and were analyzed by flow cytometry (Cyto Flex S). The data were analyzed by FlowJo software (Tree Star).

**SCFAs analysis**

Fecal levels of SCFAs were measured by gas chromatography-mass spectrometry (GC–MS) as previously described [30]. Briefly, 100 mg fecal sample was accurately weighed, and the SCFAs were extracted using a 1000 μL aliquot of methanol containing 100 μL internal standards. After grinding the mixture and sonication, the sample was settled at −20 °C for 30 min. Then, the sample was centrifuged at 13,000×g at 4 °C for 15 min. A 200 μL of supernatant was transferred to a new 1.5 mL tube. Finally, 50 mg anhydrous sodium sulfate was added to the tube and vortex, after centrifugation (13,000×g, 4 °C, 15 min), the supernatant was carefully transferred to sample vial for further analysis using Agilent 8890B-5977B GC/MS system and HP-INNOWAX (30 m × 0.25 mm × 0.25 μm) capillary column.

**Fecal microbiome analysis**

Total genomic DNA was extracted from fecal samples using QIAamp DNA Stool Mini Kit (Qiagen, Germany) according to manufacturer’s instructions. Isolated genomic DNA was amplified for the 16S rRNA V3-V4
hypervariable regions using primer pairs 338F (5′-ACT CCTACGGGAGGCAGCAG-3′) and 806R (5′-GGA CTACHVGGGTWTCTAACT-3′). The PCR products were purified with AxyPrep DNA Gel Extraction Kit (Axygen Biosciences, CA, USA). Sequencing libraries were generated using the NEXTFLEX® Rapid DNA-Seq Kit. Sequencing was performed using Illumina MiSeq platform (Illumina, San Diego, USA) according to the standard protocol (Majorbio Bio-Pharm Technology Co. Ltd., Shanghai, China). The raw 16S rRNA gene sequences were quality-filtered by fastp (version 0.20.0) and merged by FLASH (version 1.2.7). Operational taxonomic units (OTUs) were assigned a 97% similarity cutoff for clustering (UPARSE version 7.1) and chimeric sequences were identified and removed. OTUs were analyzed by RDP Classifier version 2.2 against the 16S rRNA database (e.g. Silva v138) using confidence threshold of 0.7. The Alpha diversity was measured using the Chao, Simpson, Ace and Observed species indexes. The beta diversity was conducted through Principal coordinate analysis (PCoA) according to Bray–Curtis distance. The abundance of taxa difference between groups was analyzed using Kruskal–Wallis test. Differential enrichment of gut microbiota was analyzed by linear discriminant analysis (LDA) effect size (LEfSe). Functional profiles of pathway enrichment analysis were performed using Kyoto Encyclopedia of Genes and Genomes (KEGG) and cluster of orthologous groups of proteins (COG) database by Phylogenetic Investigation of Communities by Reconstruction of Unobserved States (PICRUSt) [31]. Spearman correlation was applied to investigate the associations between fecal SCFAs, serum cytokines, and the composition of the gut microbiome.

Statistical analysis
Data were presented as mean±SEM or median with interquartile range. To determine significance among the three groups, the Kruskal–Wallis test was used for non-normally distributed data analysis, and one-way ANOVA followed by Tukey’s test was used for normally distributed data. All statistical analyses and graph generation were performed by using Graph Pad Prism (version 9.0.0). P<0.05 was considered to be statistically significant.

Results
P. pentosaceus CECT 8330 protects DSS-induced colitis
To examine the protective effect of P. pentosaceus CECT 8330 on DSS-induced colitis in mice, we treated the mice with P. pentosaceus CECT 8330 prior to or 2 days after DSS administration for 5 days (Fig. 1A, Additional file 1: Fig. S1A). As shown in Fig. 1, P. pentosaceus CECT 8330 treatment significantly protected DSS-induced loss of weight (Fig. 1B, Additional file 1: Fig. S1B), shortening of colon length (Fig. 1C, D, Additional file 1: Fig. S1C, D), DAI (Fig. 1E, Additional file 1: Fig. S1E) and CDMI (Fig. 1F, Additional file 1: Fig. S1F) scores in both female and male mice. Histologically, control groups showed intact colonic epithelial cells (Fig. 2A, Additional file 1: Fig. S2A), while DSS group showed incomplete mucosal structures, crypt abscesses, ulcers, and extensive inflammatory cell infiltration in the colonic tissues (Fig. 2B, Additional file 2: Figure S2B). P. pentosaceus CECT 8330 partially protected the mucosal architecture and goblet cell loss, and reduced inflammatory cell infiltration (Fig. 2C, Additional file 2: Figure S2C). The HI score was significantly decreased in mice treated with P. pentosaceus CECT 8330 (Fig. 2D, Additional file 2: Figure S2D). In addition, administration of P. pentosaceus CECT 8330 from day 2 to 7 of DSS treatment also protected the symptoms of colitis (Additional file 1: Figure S1, Additional file 2: Figure S2D and E).

P. pentosaceus CECT 8330 induces tight junction proteins expression
The intestinal epithelial cells are linked by tight junctions, which form the intestinal barrier. Tight junctions are composed of transmembrane and cytoplasmic scaffolding tight junction proteins (TJP), including ZO-1 and occludin. Different kinds of TJP interact with each other tightly to form an integrated intestinal epithelial barrier [32]. Thus, we next examined ZO-1 and Occludin expression in colon tissue using Western blot. As presented in Fig. 3, colon tissue of mice from DSS+ CECT 8330 group showed increased ZO-1 and Occludin protein levels as compared with DSS group.

P. pentosaceus CECT 8330 increases the ratio of CD4⁺CD25⁺Foxp3⁺ Treg cells
We examined the ratio of CD4⁺CD25⁺Foxp3⁺ Treg cells in colonic LPLs of mice from three groups using flow cytometry. As presented in Fig. 4, the proportion of CD4⁺CD25⁺Foxp3⁺ Treg cells was significantly downregulated in DSS group, while P. pentosaceus CECT 8330 treatment significantly increased the ratio of CD4⁺CD25⁺Foxp3⁺ Treg cells in the colonic tissue.

P. pentosaceus CECT 8330 modulates cytokine expression
As shown in Fig. 5, serum levels of the inflammatory cytokines, IL-1β, TNF-α, IL-6 were significantly increased, and IL-10 level was decreased in mice from DSS group as compared with Control group. P. pentosaceus CECT 8330 treatment decreased the serum levels of IL-1β, TNF-α, IL-6, and increased the IL-10 level.
**P. pentosaceus** CECT 8330 modulates the fecal SCFAs levels
Compared with Control group, acetic acid, propionic acid, butyric acid, and valeric acid levels were decreased in DSS group. In contrast, *P. pentosaceus* CECT 8330 treatment increased the levels of acetic acid, propionic acid, butyric acid, and valeric acid. In addition, hexanoic acid level was elevated in DSS group, but *P. pentosaceus* CECT 8330 reduced the hexanoic acid level in DSS+CECT 8330 group. No significant changes were found in the levels of isobutyric acid, isovaleric acid, and isocaproic acid among the three groups (Fig. 6).

**P. pentosaceus** CECT 8330 modifies gut microbiota composition
Gut microbiota composition was determined by 16S rRNA gene high throughout sequencing. As shown in Fig. 7, analysis of *alpha* diversity revealed both the richness and diversity (calculated in observed species, ACE, Chao1, and Simpson indexes) were lower in DSS group and DSS+CECT 8330 group than Control group. Although an increasing trend of *alpha* diversity was observed in DSS+CECT 8330 group, no statistical difference was achieved as compared with DSS group. Analysis of the *beta* diversity calculated on the Bray–Curtis dissimilarity of observed OTUs, phylum level, genus level, showed that fecal microbial community of DSS group apart from that of Control group. *P. pentosaceus* CECT 8330 treatment modulated the gut microbiota composition of DSS-induced dysbiosis toward to Control group.

The bacterial microbiota was dominated by phyla Firmicutes, Bacteroidetes, Proteobacteria, Tenericutes and Actinobacteria in all three groups (Additional file 3: Fig. S3). Inter-group comparisons of taxonomic profiles at the genus level revealed that DSS group exhibited lower relative abundances of *norank_f_Muribaculaceae*, *Lactobacillus*, and *Lachnospiraceae_NK4A136_group* (Additional file 4: Fig. S4). Notably,
supplementation with *P. pentosaceus* CECT 8330 clearly ameliorated this effect of DSS on the gut microbiota (Fig. 8A).

LEfSe analysis identified 32 taxa that were differentially abundant in the Control, DSS and DSS + CECT 8330 groups. Phyla Firmicutes, class Bacilli, order Lactobacillales, and genera Roseburia, *Candidatus Arthromitus* were enriched in Control group. In comparison with the Control group, DSS treatment increased the abundances of class Clostridai, 5 orders, including Oscillospirales and Clostridiaceae, 6 families (Oscillospiraceae, Ruminococcaceae, etc.), and 8 genera, such as *Colidextribacter*, *Oscillibacter*, while order Peptostreptococcales-Tissierellales, family Peptostreptococcaceae, and genera *unclassified_f_Ruminococcaceae*, *Eubacterium_fissicatena_group*, *Romboutsia*, *Christensenella*, and *unclassified_f_Peptostreptococcaceae* were enriched in DSS + CECT 8330 group (Fig. 8B).
Fig. 5  *P. pentosaceus* CECT 8330 modulates serum cytokines levels in DSS treated mice. Serum IL-6, IL-1β, TNF-α, and IL-10 levels were measured by ELISA in mice from the Control, DSS and DSS + CECT 8330 groups. Significance was determined by ANOVA with Tukey’s analysis. *P < 0.05, **P < 0.01, ***P < 0.001

Fig. 6  *P. pentosaceus* CECT 8330 increases the levels of short-chain fatty acids (SCFAs). Acetic acid, propionic acid, butyric acid, valeric acid, isobutyric acid, isovaleric acid, hexanoic acid, and isohexanoic acid of fecal samples from the Control, DSS and DSS + CECT 8330 groups were determined by using GC–MS. Significance was determined by ANOVA with Tukey’s analysis. *P < 0.05, **P < 0.01, ***P < 0.001
Furthermore, LDA scores (> 3.5) derived from LEfSe analysis at genus level identified several bacterial genera that discriminated the Control, DSS and DSS + CECT 8330 group. Notable high abundances of *Lactobaillus*, *Bifidobacterium*, *Candidatus Arthromitus* were found in mice from the Control group, while the DSS enriched the abundances of *Lachnospiraceae_NK4A136_group*, *Rikenellaceae_RC9_gut_group*, *norank_f_norank_o_Clostridia_UCG-014*, *norank_f_Desulfovibrionales*, *unclassified_f_Lachnospiraceae*, *Parasutterella*, *Odoribacter*, *Clostridium_sensu_stricto_1*, *Clostridiales_vadinBB60_group*, *Colidextribacter*, *Oscillibacter*, and *Oscillibacter*. The abundances of *unclassified_f_Prevotellaceae*, *Escherichia-Shigella*, *Eubacterium_fissicatena_group*, *unclassified_f_Ruminococcaceae*, *Romboutia*, *Christensenella*, *unclassified_f_Peptostreptococcaceae*, and *NK4A214_group* were enriched in DSS + CECT 8330 group (Fig. 8C).

**Functional profile of the gut microbiome**

KEGG and COG pathway analysis were performed to explore potential differences in the functional composition of the microbiome in three groups using PICRUSt. The microbiome of mice in DSS group showed lower abundance in KEGG pathways of replication and repair, translation, nucleotide metabolism, glycan biosynthesis and metabolism, folding, enzyme families, metabolism of terpenoids and polyketides, metabolism of other amino acids, cell growth and death, infectious diseases, signaling molecules and interaction than the mice in

![Image](image_url)
Fig. 8 (See legend on previous page.)
Control group (Fig. 9A). Higher abundance in KEGG pathways of cellular processes and signaling, cell motility, transcription, signal transduction was identified in DSS group (Fig. 9A). In addition, COG pathway analysis showed similar patterns of abundance changes, such as lower abundance of translation, ribosomal structure and biogenesis, and higher abundance of cell motility, transcription, and signal transduction mechanisms in DSS group (Fig. 9B). *P. pentosaceus* CECT 8330 treatment significantly ameliorated the change of pathways abundance induced by DSS (Fig. 9).

**Covariance between serum cytokines, fecal SCFAs, and the gut microbiome**

To examine the relationship between members of the gut microbiota, serum cytokines, and fecal SCFAs, we performed unsupervised clustering of the top 50 abundant bacteria genera, serum cytokines and fecal SCFAs. The results revealed that the increased abundance of several genera by DSS were positively correlated with serum inflammatory cytokines (IL-6, IL-1β, and TNF-α) and negatively associated with IL-10, SCFAs, including *Lachnospiraceae* _NK4A136_group, *norank_f_norank_o_Clostridia_UCG-014*, *Clostridium_sensu_stricto_1*, *Clostridium_vadinBB60_group*, *Oscillibacter*, *GCA_900066575*, and *norank_f_Ruminococcaceae*. In contrast, several genera increased by *P. pentosaceus* CECT 8330 treatment were positively correlated with IL-10 and major SCFAs, and negatively associated with IL-6, IL-1β, and TNF-α, such as *norank_f_Muribaculaceae*, *Lactobacillus*, *Dubosiella*, and *Bifidobacterium* (Fig. 10).

**Discussion**

Changes in the gut microbiota play a critical role in the pathogenesis of IBD. Altered microbes increase susceptibility to IBD by affecting intestinal immunity and epithelial barrier function through gut microbiota-derived metabolites in genetically susceptible hosts [33]. Both quantitative and qualitative alternations of gut microbiota composition were presented in IBD patients that characterized by the decline in bacterial species and genera, and changes in the proportion of different bacteria [18]. For example, increased abundance of potentially pathogenic bacteria belonging to Proteobacteria (e.g., *E. coli* and *Klebsiella*), and reduced abundance of potentially beneficial bacteria of Firmicutes (e.g., *Faecalibacterium prausnitzii* and *Ruminococci*) were found in the majority of IBD patients [11, 34, 35]. The gut microbiota dysbiosis and dysregulated immune responses provide a strong theoretical rationale for exploring microbial-based and microbial-targeted therapies in patients with IBD. Several approaches have been used to manipulate the dysbiotic microbiota in both experimental colitis animal models and IBD patients, such as probiotics administration [21, 22].

Probiotics refer to live microorganisms that exert a beneficial effect on the health of the host when administered ingested in adequate doses [36]. To date, many probiotic strains have been investigated in IBD clinical trials. Several probiotic strains achieved a favorable outcome as mono or adjuvant therapy in IBD, especially in UC patients, such as *E. coli* Nissle 1917, LGG, *Lactobacillus reuteri* ATCC 55730, and *Bifidobacterium longum* BB536. In addition to the most studied probiotic strains that belong to *Lactobacillus* and *Bifidobacterium* genera, several other strains have been revealed to possess probiotic characteristics [37]. *P. pentosaceus* is one type of lactic acid bacteria (LAB) that belongs to the Lactobacillaceae family. As promising probiotic candidates, the functional roles of several *P. pentosaceus* strains have been investigated in recent years [38]. Many *P. pentosaceus* strains isolated from different sources were proven to be linked with the human gastrointestinal tract [38]. In animal studies, *P. pentosaceus* strains have been reported that could improve acute liver failure, obesity, constipation, fatty liver, and intestinal inflammation [39–43]. In this study, we further revealed that a *P. pentosaceus* strain isolated from healthy children, CECT 8330, protected DSS-induced experimental colitis in mice as demonstrated by inhibition of weight loss, colon length shortening, and intestinal mucous damage. Together with previous studied *P. pentosaceus* strains with anti-inflammation ability, such as *P. pentosaceus* L105, it suggests *P. pentosaceus* may have the potential for IBD therapy [43].

Intestinal epithelial damage is the initiating event in chemically induced colitis models [27]. Our results showed that DSS significantly decreased the expression of ZO-1 and Occludin, while administration of *P. pentosaceus* CECT 8330 increased the expression of ZO-1 and Occludin that attenuated the DSS-induced epithelial damage. Inflammatory responses mediated by proinflammatory cytokines further aggravate the colitis [44]. Our data showed that the upregulated serum levels of IL-6, IL-1β, and TNF-α induced by DSS were decreased by *P. pentosaceus* CECT 8330 treatment. IL-10, an anti-inflammatory cytokine secreted by a range of immune cells, including Treg cells, plays a critical role in maintaining mucosal homeostasis [45]. It has been shown that *P. pentosaceus* CECT 8330 has the ability to induce IL-10 production in THP-1 macrophages [25]. In this study, we further showed that *P. pentosaceus* CECT 8330 increased the level of IL-10 in DSS-treated mice, which may mediated by increasing the ratio of CD4+CD25+FOXP3+ Treg cells in the colon.
Fig. 9  Functional profile of the gut microbiome. The bar charts of KEGG (A) and COG (B) pathways showing 14 and 10 significant differences among the Control, DSS and DSS+CECT8330 groups, respectively. Significance was determined by Kruskal–Wallis test. *P < 0.05, **P < 0.01
Previous studies have suggested that the actions of probiotics are major through normalizing the altered gut microbiota [21, 22]. In this study, dysbiosis of gut microbiota by DSS treatment was determined by both alpha and beta diversity that compared with Control group. LEfSe analysis identified more than 30 taxa were differentially abundant in the Control, DSS and DSS + CECT 8330 groups, such as Phyla Firmicutes, class Bacilli, order Lactobacillales, and genera Roseburia, Candidatus_Arthromitus were enriched in Control group, order Clostridiaceae and genera Clodixtribacter, Oscillibacter were abundant in DSS-treated mice. P. pentosaceus CECT 8330 treatment could significantly recover the dysregulated bacteria genera induced by DSS. Microbial marker in genus level that discriminated the three group were further identified, including high abundances of Lactobaillus, Bifidobacterium, Candidatus_Arthromitus in the Control group, high abundances of Lachnospiraceae_NK4A136_group, Rikenellaceae_RC9_gut_group in the DSS group, and high abundances...
of unclassified_f_Prevotellaceae in DSS + CECT 8330 group. Taken together, P. pentosaceus CECT 8330 treatment could partially correct the changes of gut microbiota composition induced by DSS.

Microbiota-host interactions are predominant mediated by metabolites that derived from bacterial metabolism of dietary substrates, modification of host molecules, or directly from bacteria, such as SCFAs [33, 46]. In IBD patients, the levels of SCFAs and intestinal bacteria that produce SCFAs were significantly reduced [47, 48]. Our study found decreased abundance SCFAs producing bacteria that correlated with decreased SCFAs levels in the fecal samples of DSS group as compared to the Control group, such as norank_f_Muribaculaceae, Bifidobacterium, and Lactobacillus. The abundance changes of SCFAs producing bacteria were most likely responsible for the decreased level of several major SCFAs, including acetic acid, propionic acid, and butyric acid. Although hexanoic acid level was slightly elevated in DSS group, P. pentosaceus CECT 8330 significantly reduced the hexanoic acid level in DSS + CECT 8330 group. Moreover, SCFAs exert immunomodulatory effects by increasing the number of intestinal Treg cells that maintain epithelial homeostasis [49]. We showed that P. pentosaceus CECT 8330 administration increased the abundances of SCFAs producing bacteria and fecal SCFAs levels. Covariance analysis further revealed that the increased abundance of several genera by DSS were positively correlated with serum inflammatory cytokines and negatively associated with IL-10, SCFAs, while several genera increased by P. pentosaceus CECT 8330 treatment were positively correlated with IL-10 and major SCFAs, and negatively associated with IL-6, IL-1β, and TNF-α.

Understanding functional interactions among microbiota within the host gut are critical to explore the pathogenesis of IBD. Studies have shown that the metabolic activities of the gut microbiota that reflected in the genes encoded into their genomes were consistently perturbed in IBD patients [9, 50, 51]. Our previous study showed that microbial function was significantly altered in the gut microbiota of pediatric CD patients that characterized by downregulation of several metabolic capacities, including KEGG pathway of replication and repair, amino acid metabolism, glycan biosynthesis and metabolism, and nucleotide metabolism [52]. Similarly, the KEGG and COG pathway analysis indicated that the dysbiosis of gut microbiota induced by DSS in mice was strongly associated with dysregulation of basic metabolic processes, such as nucleotide metabolism, glycan biosynthesis and metabolism. The declining of nucleotide metabolism could affect the metabolism of purine base by intestinal bacteria [53]. The downregulation of glycan biosynthesis and metabolism function suggested that the ability of metabolize polysaccharides into monosaccharides by gut bacteria may decrease. Furthermore, lower abundance of genes of replication and repair, translation, folding, enzyme families, infectious diseases, metabolism of terpenoids and polyketides, metabolism of other amino acids, cell growth and death, signaling molecules and interaction indicated that those pathways may be important for intestinal immune homeostasis. On the contrary, increasing abundance of genes involved in cellular processes and signaling, cell motility, transcription, signal transduction was observed in DSS group implied their roles in mediating intestinal inflammation and immune dysfunction. The KEGG and COG pathway analysis further revealed that P. pentosaceus CECT 8330 could partially recover the pathways altered by DSS. Given the complicated metabolic interactions occurring among bacteria and the host, more efforts are needed to uncover the role of microbial function in IBD pathogenesis in the future.

**Conclusions**

In conclusion, the P. pentosaceus CECT 8330 administration protected the DSS-induced colitis, modulated the gut microbial composition and function, immunological profiles, and gut barrier function. Well-defined P. pentosaceus strains may have the potential for IBD therapy in the future.

**Abbreviations**

IBD: Inflammatory bowel diseases; P. pentosaceus; Pediococcus pentosaceus; DSS: Dextran sulfate sodium; Treg: Regulatory T cells; SCFAs: Short-chain fatty acids; DAi: Disease activity index; CD: Crohn’s disease; IL: Interleukin; UC: Ulcerative colitis; TNF: Tumor necrosis factor; FMT: Fecal microbiota transplantation; LGG: Lactobacillus rhamnosus GG; PBS: Phosphate-buffered saline; SPF: Specific pathogen-free; CMX: Colonic mucosa damage index; H&E: Hematoxylin and eosin; HI: Histological index; SDS: Sodium dodecyl sulfate; PMSF: Phenylmethylsulfonyl fluoride; SDS-PAGE: SDS–polyacrylamide gel electrophoresis; LAB: Lactic acid bacteria; PVDF: Polyvinylidene difluoride; LPLs: Lamina propria lymphocytes; GC–MS: Gas chromatography-mass spectrometry; OTUs: Operational taxonomic units; PcoA: Principal coordinate analysis; TJIP: Tight junction proteins.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s12967-022-03235-8.

**Additional file 1: Fig. S1.** P. pentosaceus CECT 8330 protects DSS-induced colitis in male mice. (A) Schematic of animal experimental procedures (5 mice/group). (B) Changes of body weight (%). (C) Colon length shortening at day 7. (D) Representative images of the colon at day 7. (E) Disease activity index (DAI) scores. (F) Colon mucosal damage index (CMOI) scores at day 7. Significance was determined by ANOVA with Tukey’s analysis, *P < 0.05, **P < 0.01, ***P < 0.001.

**Additional file 2: Fig. S2.** P. pentosaceus CECT 8330 protects DSS-induced colon epithelial damage in male mice. Representative H&E stained colon sections (magnification 100 ×) images (A, B, C, D) and histopathology...
score (E). Significance was determined by ANOVA with Tukey’s analysis, *P < 0.01, **P < 0.001.

Additional file 3: Fig. S3. The species composition of fecal samples at phylum level among the Control, DSS and DSS + CECT 8330 groups.

Additional file 4: Fig. S4. The species composition of fecal samples at genus level among the Control, DSS and DSS + CECT 8330 groups.

Acknowledgements
Not applicable.

Authors’ contributions
YW and TZ conceived the study, FO, FX, XL, and YL performed the experiment. DF analyzed the omics data and created figures. DF and YW interpreted the data, and wrote the manuscript. GY and TZ edited the manuscript. All authors read and approved the final manuscript.

Funding
This work was supported by the grants from the National Natural Science Foundation of China (Grant Number 81900472, 81870373), Shanghai Hospital Development Center New Frontier Technology Joint Research Project (Grant Number SHDC12017115), and Shanghai Science and Technology Committee (19140904300). The funders had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
This study was approved by the Animal Ethics Committee of Shanghai Children’s Hospital (SHCH-IACUC-2020-XMSB-10).

Consent for publication
Net applicable.

Competing interests
All authors declared no conflict of interest.

Author details
1 Department of Gastroenterology, Hepatology and Nutrition, Shanghai Children’s Hospital, Shanghai Jiao Tong University, 355 Luding Road, Shanghai 200062, China. 2 Institute of Pediatric Infection, Immunity and Critical Care Medicine, Shanghai Children’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200062, China.

Received: 1 September 2021 Accepted: 5 January 2022
Published online: 15 January 2022

References
1. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347:417–29.
2. Heyman MB, Kirscher BS, Gold BD, Ferry G, Baldassano R, Cohen SA, Winter HS, Fain P, King C, Smith T, El-Seraig HB. Children with early-onset inflammatory bowel disease (IBD): analysis of a pediatric IBD consortium registry. J Pediatr. 2005;146:33–40.
3. Jinhee C, Sorina K, Hee YD, Juyeon L, Won PK, Junyong G, Chang-Lim H, Youngheun J, Soo KK. Mucosal immunity related to FOXP3+ regulatory T cells. Th17 cells and cytokines in pediatric inflammatory bowel disease. J Korean Med Sci. 2018;33:e336.
4. Gai G, Yuan A. A systematic review of epidemiology and risk factors associated with Chinese inflammatory bowel disease. Front Med (Lausanne). 2018;5:183.
5. Nikolaus S, Schreiber S. Diagnostics of inflammatory bowel disease. Gastroenterology. 2007;133:1670–89.
6. Ko JK, Auyeung KK. Inflammatory bowel disease: etiology, pathogenesis and current therapy. Curr Pharm Des. 2014;20:1082–96.
7. Loddo L, Romano C. Inflammatory bowel disease: genetics, epigenetics, and pathogenesis. Front Immunol. 2015;6:551.
8. Lynch SV, Pedersen O. The human intestinal microbiome in health and disease. N Engl J Med. 2016;375:2369–79.
9. Dunn KA, Moore-Connors J, MacIntyre B, Stadnyk A, Thomas NA, Noble A, Mahdi G, Rashid M, Otley AR, Bielawski JP, Van Limbergen J. The gut microbiome of pediatric Crohn’s disease patients differs from healthy controls in genes that can influence the balance between a healthy and dysregulated immune response. Inflamm Bowel Dis. 2016;22:2607–18.
10. Maukonen J, Kolho KL, Paasela M, Honkanen J, Klemetti P, Vaarala O, Saarela M. Altered fecal microbiota in paediatric inflammatory bowel disease. J Crohns Colitis. 2015;9:1088–95.
11. Pascal P, Pozuelo M, Borrell N, Casellas F, Campos D, Santiago A, Martinez X, Varela E, Sarrabayrouse G, Machiels K, et al. A microbial signature for Crohn’s disease. Gut. 2017;66:813–22.
12. Greenblum S, Turnbaugh PJ, Borenstein E. Metagenomic systems biology of the human gut microbiome reveals topological shifts associated with obesity and inflammatory bowel disease. Proc Natl Acad Sci U S A. 2012;109:594–9.
13. Jostins L, Ripke S, Weersma RK, Duerr RH,溅泽 S, Chen CC, et al. Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491:119–24.
14. Gevers D, Kugathasan S, Denson LA, Vazquez-Baeza Y, Von Treuren W,ten R, Schwager E, Knights D, Song SJ, Yassour M, et al. The treatment-naive microbiome in new-onset Crohn’s disease. Cell Host Microbe. 2014;15:382–92.
15. Matsuoka K, Kani T. The gut microbiota and inflammatory bowel disease. Semin Immunopathol. 2013;37:47–55.
16. Sartor RB, Wu GD. Roles in intestinal bacteria, viruses, and fungi in pathogenesis of inflammatory bowel diseases and therapeutic approaches. Gastroenterology. 2017;152:327-39 e324.
17. Kang S, Deman SE, Morrison M, Yu Z, Dore J, Leclerc M, McSweeney CS. Dysbiosis of fecal microbiota in Crohn’s disease patients as revealed by a custom phylogenetic microarray. Inflamm Bowel Dis. 2016;20:343–42.
18. Khan I, Ullah N, Zha L, Bai Y, Khan A, Zhao T, Che T, Zhang C. Alteration of gut microbiota in inflammatory bowel disease (IBD): cause or consequence? IBD treatment targeting the gut microbiome. Pathogens. 2019;8:126.
19. Wang Y, Gao X, Zhang X, Xiao F, Hu H, Li X, Dong F, Sun M, Xiao Y, Ge T, et al. Microbial and metabolic features associated with outcome of infliximab therapy in pediatric Crohn’s disease. Gut Microbes. 2021;13:1–18.
20. Bernstein CN. Treatment of IBD: where we are and where we are going. Am J Gastroenterol. 2015;110:114–26.
21. Oka A, Sartor RB. Microbial-based and microbial-targeted therapies for inflammatory bowel diseases. Dig Dis Sci. 2020;65:757–88.
22. Akutski K, Stawarski A. Probiotics, prebiotics and symbiotics in inflammatory bowel diseases. J Clin Med. 2021;10:246.
23. Kruis W, Fric P, Pokromniak J, Lukas M, Fina B, Kascak M, Kamm MA, Weissmueller J, Beglinger C, Stolte M, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut. 2004;53:1617–23.
24. Saez-Lara MJ, Gomez-Llorente C, Plaza-Diaz J, Gil A. The role of probiotic lactic acid bacteria and bifidobacteria in the prevention and treatment of inflammatory bowel disease and other related diseases: a systematic review of randomized human clinical trials. Biomed Res Int. 2015;2015:505878.
25. Santas J, Fuentes M, Tormo R, Guaya-Escollas R, Lázaro E, Cuñé J. Pedio- cococcus pentosaceus CECT 8330 and bifidobacterium longum CECT 7894 show a trend towards lowering infantile excessive crying syndrome in a pilot phylogenetic microbial trial. Int J Pharma Bio Sci. 2015;6:458–66.
26. Bosch M, Rodriguez M, Garcia F, Fernández E, Fuentes MC, Cune J. Probiotic properties of Lactobacillus plantarum CECT 7315 and CECT 7316 isolated from faeces of healthy children. Lett Appl Microbiol. 2012;54:417–29.
27. Wirtz S, Popp V, Kindermann M, Gerlach K, Weigmann B, Fichtner-Feigl S, Neurath MF. Chemically induced mouse models of acute and chronic intestinal inflammation. Nat Protoc. 2017;12:295–309.
28. Zhang H, Zhang Z, Song G, Tang X, Song H, Deng A, Wang W, Wu L, Qin H. Development of an XBP1 agonist, HLJ2, as a potential therapeutic agent for ulcerative colitis. Eur J Pharm Sci. 2017;109:56–64.

29. Erben U, Loddenkemper C, Doefel K, Speckermann S, Haller D, Heimesaat MW, Zeitz M, Segmund B, Kuhl AA. A guide to histomorphological evaluation of intestinal inflammation in mouse models. Int J Clin Exp Pathol. 2014;7:4557–76.

30. Wang Z, Zhang X, Zhu L, Yang X, He F, Wang T, Bao T, Lu H, Wang H, Yang S. Inulin alleviates inflammation of alcoholic liver disease via SCFAs-inducing suppression of M1 and facilitation of M2 macrophages in mice. Int Immunopharmacol. 2020;78:106062.

31. Langille MG, Zaneveld J, Caporaso JG, McDonald D, Knights D, Reyes JA, Clemente JC, Burkepile DE, Vega Thurber RL, Knight R, et al. Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. Nat Biotechnol. 2013;31:814–21.

32. Alizadeh A, Akbari P, Garsen J, Fink-Gremmels J, Braber S. Epithelial integrity, junctional complexes, and biomarkers associated with intestinal functions. Tissue Barriers. 2021. https://doi.org/10.1080/21688370.2021.1996830.

33. Lavelle A, Sokol H. Gut microbiota-derived metabolites as key actors in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2020;17:223–37.

34. Negroni A, Costanzo M, Vitali R, Superti F, Bertuccini L, Negroni A, Costanzo M, Vitali R, Superti F, Bertuccini L, Tinari A, Minelli F, Di Nardo G, Nuti F, Pirovano M, et al. Characterization of adherent-invasive Escherichia coli isolated from pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:913–24.

35. Takahashi K, Nishida A, Fujimoto T, Fujii M, Shiyoa M, Imaeda H, Inatomi O, Bamba S, Sugimoto M, Andoh A. Reduced abundance of butyrate-producing bacteria species in the fecal microbial community in Crohn’s disease. Digestion. 2016;93:59–65.

36. Hill C, Guarner F, Reiner F, Bertuccini L, Tinari A, Minelli F, Nuti F, Pirovano M, et al. Characterization of adherent-invasive Escherichia coli isolated from pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:913–24.

37. Cunningham M, Azzarate-Penl MA, Barnard A, Benoit V, Grimaldi R, Guy-onnel D, Holczer HD, Hunter K, Manurung S, Obis D, et al. Shaping the future of probiotics and prebiotics. Trends Microbiol. 2021;29:667–85.

38. Jiang S, Cai L, Lv L, Li L. Pediococcus pentosaceus, a future additive or prebiotic candidate. Microb Cell Fact. 2021;20:45.

39. Lv LX, Li YD, Hu XJ, Shi HY, Li LJ. Whole-genome sequence assembly of Pediococcus pentosaceus LI05 (CGMCC 7049) from the human gastrointestinal tract and comparative analysis with representative sequences from three food-borne strains. Gut Pathog. 2014;6:36.

40. Zhao X, Higashikawa F, Noda M, Kawamura Y, Matoba Y, Kumagai T, Okumura M, Zeitz M, Siegmund B, Kuhl AA. A guide to histomorphological evaluation of intestinal inflammation in mouse models. Int J Clin Exp Pathol. 2014;7:4557–76.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.